This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;284:2178.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved arsenic trioxide (Trisenox injection, Cell Therapeutics Inc, Seattle, Wash) for induction of remission or consolidation in patients with acute promyelotic leukemia (APL) who are refractory to or have relapsed from all transretinoic acid– and anthracycline-based chemotherapy.

Arsenic trioxide converts immature cancerous white blood cells into normal white blood cells, but the mechanism is not fully understood. The drug's benefits were found to outweigh its risks in a study of 40 patients with relapsed or refractory APL who had been treated with an anthracycline and a retinoid regimen (ATRA). Patients received arsenic trioxide, 0.15 mg/kg per day intravenously for 1 to 2 hours, until the bone marrow was cleared of leukemic cells or a maximum of 60 days.

Twenty-eight (70%) of the 40 patients had a complete remission of leukemia in a median of 51 days. There were 18 complete responders (75%) among the 24 patients who . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?